Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EDGE

Financiado

Cerrado

Training network providing cutting EDGE knowlEDGE on Herpes Virology and Immunol...

Training network providing cutting EDGE knowlEDGE on Herpes Virology and Immunology Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe diseases, especially in children, immunocompromised individuals, and elderly. There are current... ver más

31/10/2020

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-10-31

MSCA-ITN-2015-ETN: Marie Skłodowska-Curie Innovative T...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

580.16K€ | Lider

MEDIASET ESPAÑA COMUNICACION

1.25M€ | Participante

Janssen Vaccines (f.k.a. Cru...

255.37K€ | Participante

UOXF

273.29K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

NKT IN HERPES The role of natural killer T cells in the early stages of th... 180K€ Cerrado

ADITEC Advanced Immunization Technologies 41M€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

ROCSI Romanian Centre of Excellence for Systems Immunology 400K€ Cerrado

HIV HOST FACTORS HOST FACTORS THAT FACILITATE AND RESTRICT HIV 1 REPLICATION 2M€ Cerrado

Duración del proyecto: 54 meses Fecha Inicio: 2016-04-05
Fecha Fin: 2020-10-31

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe diseases, especially in children, immunocompromised individuals, and elderly. There are currently no safe vaccines against herpesvirus infections and current treatments are not satisfactory. With new insights into the molecular basis for diseases caused by immunodeficiency, and with the increasing numbers of elderly in Europe, there is now an unmet demand for improved treatments of herpesvirus infections. Combined with the progress in basic herpesvirus research, this calls for education of a new generation of scientists with strong research skills, advanced insights into disease mechanisms, and understanding of how industry brings innovative research into the market. In this application we propose an interactive education program for early stage researchers (ESR) in leading European laboratories, hospitals, and biotech companies. The focus will be on the virology and immunology of herpesvirus infections in the context of basic research as well as application of research-acquired knowledge. Our program will prepare the ESRs to manage goal-oriented interactions between academia, the clinics, and the biotech industry. The ESRs will acquire broad theoretical and methodological expertises involving several sectors to obtain the skills required for overcoming the cultural gaps From Bench to Bedside and From Discovery to Innovation. This can only be achieved through a network-based approach. We propose to develop a platform to educate the next generation of scientists to solve the outstanding problems in prevention and treatment of herpesvirus infections. The ESRs will be ideally trained to translate cutting-edge discoveries to novel products and to innovative treatment serving the European people, and hence to improve handling of present and emerging health challenges, as well as to foster the European biopharmaceutical industry sector.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores